|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
US5932572A
(en)
*
|
1992-02-21 |
1999-08-03 |
Alcon Laboratories, Inc. |
Topical anti-glaucoma compositions
|
|
EP0625903B1
(de)
*
|
1992-02-21 |
1998-08-12 |
Alcon Laboratories, Inc. |
Topische Antiglaukoma Zusammensetzungen, enthaltend Karbonhydrasehemmer und Beta-Blocker
|
|
EP0660703A1
(de)
*
|
1992-09-17 |
1995-07-05 |
Alcon Laboratories, Inc. |
Topisch anzuwendende arzneimittel enthaltend kohlensäureanhydraseinhibitoren
|
|
SE9301877D0
(sv)
*
|
1993-06-02 |
1993-06-02 |
Kabi Pharmacia Ab |
In situ gel for therapeutic use
|
|
EP0708646A1
(de)
*
|
1994-05-06 |
1996-05-01 |
Alcon Laboratories, Inc. |
Verwendung von vitamin e tocopherolderivaten in ophthalmischen präparaten
|
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
|
US5696166A
(en)
*
|
1995-10-31 |
1997-12-09 |
Yanni; John M. |
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
|
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
|
EP1057486A1
(de)
*
|
1995-11-17 |
2000-12-06 |
Alcon Laboratories, Inc. |
Verwendung einer Medikamentenkombination zur Behandlung von Glaukom
|
|
FR2754712B1
(fr)
|
1996-10-17 |
1999-09-03 |
Merck Sharp Dohme Chibret Lab |
Compositions ophtalmiques
|
|
CH690814A5
(it)
*
|
1996-11-04 |
2001-01-31 |
Applied Pharma Res |
Composizioni per uso topico contenenti polisaccaridi solfati.
|
|
ZA989513B
(en)
|
1997-10-21 |
1999-04-21 |
Alcon Lab Inc |
Compositions containing histamine H2 agonists and methods of use in treating dry eye
|
|
US6174524B1
(en)
|
1999-03-26 |
2001-01-16 |
Alcon Laboratories, Inc. |
Gelling ophthalmic compositions containing xanthan gum
|
|
US6261547B1
(en)
|
1998-04-07 |
2001-07-17 |
Alcon Manufacturing, Ltd. |
Gelling ophthalmic compositions containing xanthan gum
|
|
US6462080B1
(en)
|
1998-12-24 |
2002-10-08 |
Alcon Manufacturing, Ltd. |
Prostaglandin E receptor agonists for treatment of dry eye
|
|
AU2183900A
(en)
|
1998-12-24 |
2000-07-31 |
Alcon Laboratories, Inc. |
Ep4 receptor agonists for treatment of dry eye
|
|
DK1616869T3
(da)
|
1999-01-25 |
2012-05-07 |
Nat Jewish Health |
Substituerede porphyriner og deres terapeutiske anvendelse
|
|
PT1225898E
(pt)
|
1999-11-01 |
2003-10-31 |
Alcon Inc |
Composicoes farmaceuticas contendo um farmaco antibiotico de fluoroquinolona e goma xantana
|
|
US6552084B2
(en)
|
1999-11-09 |
2003-04-22 |
Alcon Universal Ltd. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
|
US6458854B2
(en)
|
1999-11-09 |
2002-10-01 |
Alcon Universal Ltd. |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
|
|
EP1228026B1
(de)
|
1999-11-09 |
2004-01-02 |
Alcon Inc. |
15-hydroxyeicosatetraensäure verwandte verbindungen und anwendungsverfahren
|
|
MXPA02004703A
(es)
|
1999-11-09 |
2004-09-10 |
Alcon Inc |
Composiciones que contienen derivados de acido hidroxieicostetraenoico y metodos de uso para tratar trastornos de resequedad en los ojos.
|
|
PL356127A1
(en)
|
1999-11-09 |
2004-06-14 |
Alcon Inc. |
Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye
|
|
MXPA02004702A
(es)
|
1999-11-09 |
2004-09-10 |
Alcon Inc |
Analogos interrumpidos por heteroatomos de acido 15-hidroxieicosatetraenoico y metodos de uso.
|
|
EP1228030B1
(de)
|
1999-11-09 |
2005-06-01 |
Alcon Inc. |
Benzenoidderivate von 15-hydroxyeicosatetraensäure und verfahren zur verwendung zur behandlung des trockenen auges
|
|
AU1101301A
(en)
|
1999-11-09 |
2001-06-06 |
Alcon Universal Limited |
2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
|
|
US6803385B2
(en)
|
1999-11-09 |
2004-10-12 |
Alcon, Inc. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
|
CA2388044A1
(en)
|
1999-11-09 |
2001-05-17 |
Alcon, Inc. |
Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
|
|
ES2215752T3
(es)
|
1999-11-09 |
2004-10-16 |
Alcon, Inc |
Lipoxina a4 y analogos para el tratamiento del ojo seco.
|
|
US6320062B1
(en)
|
1999-11-09 |
2001-11-20 |
Alcon Universal Ltd. |
15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
|
|
CA2386333A1
(en)
|
1999-11-09 |
2001-05-17 |
Alcon, Inc. |
3-heteroatom substituted and two carbon homologs 15-hete and methods of use
|
|
US6353032B1
(en)
|
1999-11-09 |
2002-03-05 |
Alcon Universal Ltd. |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
|
|
US6576663B2
(en)
|
1999-12-22 |
2003-06-10 |
Alcon, Inc. |
6-Keto prostaglandin F1α and analogs for treating dry eye
|
|
PL199321B1
(pl)
|
2000-07-28 |
2008-09-30 |
Alcon Inc |
Kompozycje farmaceutyczne zawierające tobramycynę i gumę ksantanową
|
|
PE20020578A1
(es)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
Una composicion de antibiotico topico para el tratamiento de infecciones oculares
|
|
US20030060447A1
(en)
*
|
2002-04-24 |
2003-03-27 |
Mutlu Karakelle |
Non-aspirating transitional viscoelastics for use in surgery
|
|
WO2002040056A2
(en)
|
2000-11-06 |
2002-05-23 |
Alcon, Inc |
Carrageenan viscoelastics for ocular surgery
|
|
DE60213230T2
(de)
|
2001-05-21 |
2006-11-23 |
Alcon Inc. |
Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit
|
|
BR0209882A
(pt)
*
|
2001-05-21 |
2004-06-08 |
Alcon Inc |
Método para o tratamento de distúrbios de olho seco
|
|
US6872382B1
(en)
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
|
US6740674B2
(en)
|
2001-05-21 |
2004-05-25 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
|
AU2002312194B8
(en)
*
|
2001-06-01 |
2008-05-15 |
Aeolus Sciences, Inc. |
Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
|
|
US6645994B1
(en)
|
2001-06-01 |
2003-11-11 |
Alcon, Inc. |
Method of treating dry eye disorders
|
|
US6750250B1
(en)
|
2001-07-12 |
2004-06-15 |
Alcon, Inc. |
11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
|
|
US20040220089A1
(en)
*
|
2001-10-03 |
2004-11-04 |
Ellis Edward J. |
Ophthalmic preparation containing glycoprotein
|
|
US20040214754A1
(en)
*
|
2001-10-03 |
2004-10-28 |
Ellis Edward J. |
Ophthalmic preparation containing glycomacropeptide
|
|
CA2464736A1
(en)
*
|
2001-10-23 |
2003-05-15 |
Oklahoma Medical Research Foundation |
Beta-secretase inhibitors and methods of use
|
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
BR0307898A
(pt)
*
|
2002-02-22 |
2004-12-07 |
Pharmacia Corp |
Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
|
|
EP1476135A1
(de)
*
|
2002-02-22 |
2004-11-17 |
Pharmacia Corporation |
Ophthalmische formulierung mit gummi-system
|
|
EP2316459B1
(de)
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
2,4-Pyrimidindiaminen zur Behandlung oder Vorbeugung von Autoimmunerkrankungen
|
|
WO2005018646A1
(ja)
*
|
2003-08-21 |
2005-03-03 |
Sucampo Ag |
眼科用組成物
|
|
US8580851B2
(en)
|
2002-08-21 |
2013-11-12 |
Sucampo Ag |
Ophthalmic solution
|
|
AU2003303623A1
(en)
*
|
2002-12-20 |
2004-07-29 |
Alcon, Inc. |
Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
|
|
WO2005013996A2
(en)
|
2003-08-07 |
2005-02-17 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
|
|
JP2008513495A
(ja)
*
|
2004-09-17 |
2008-05-01 |
コメンティス，インコーポレーテッド |
ベータ−セクレターゼ活性を阻害する二環式化合物およびその使用方法
|
|
EP1799660A2
(de)
*
|
2004-09-17 |
2007-06-27 |
Comentis, Inc. |
Aminohaltige verbindungen zur inhibition der aktivität von memapsin-2-beta-sekretase und verfahren zu ihrer verwendung
|
|
US9512125B2
(en)
*
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
|
KR20080015079A
(ko)
*
|
2005-04-08 |
2008-02-18 |
코멘티스, 인코포레이티드 |
베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
|
|
CA2642229C
(en)
|
2006-02-24 |
2015-05-12 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
TW200808375A
(en)
|
2006-05-12 |
2008-02-16 |
Otsuka Pharma Co Ltd |
Hydrogel suspension and manufacturing process thereof
|
|
US8778977B2
(en)
|
2006-06-30 |
2014-07-15 |
Sunesis Pharmaceuticals, Inc. |
Pyridinonyl PDK1 inhibitors
|
|
EP2420505A1
(de)
|
2006-11-21 |
2012-02-22 |
Rigel Pharmaceuticals, Inc. |
Prodrug-Salze von 2,4-Pyrimidindiaminverbindungen und Anwendungen davon
|
|
KR20080076667A
(ko)
*
|
2007-02-15 |
2008-08-20 |
주식회사 중외제약 |
요변성 약학 조성물
|
|
EP2170283B1
(de)
|
2007-06-22 |
2019-01-09 |
Board of Regents, The University of Texas System |
Bildung eines stabilen submikron-peptids oder von proteinteilchen durch dünnfilm-gefrieren
|
|
US20100286145A1
(en)
*
|
2007-07-26 |
2010-11-11 |
Comentis, Inc. |
Isophthalamide derivatives inhibiting beta-secretase activity
|
|
KR20100059919A
(ko)
*
|
2007-09-24 |
2010-06-04 |
코멘티스, 인코포레이티드 |
치료를 위한 베타-세크레타제 억제제로서 (3-히드록시-4-아미노-부탄-2일)-3-(2-티아졸-2-일-피롤리딘-1-카르보닐) 벤즈아미드 유도체 및 관련 화합물
|
|
JP2011517313A
(ja)
|
2007-12-11 |
2011-06-02 |
ビアメト ファーマシューティカルズ，インク． |
金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
|
|
CA2717825A1
(en)
*
|
2008-03-07 |
2009-09-11 |
Sun Pharma Advanced Research Company Ltd. |
Opthalmic composition
|
|
US11382895B2
(en)
|
2008-05-23 |
2022-07-12 |
National Jewish Health |
Methods for treating injury associated with exposure to an alkylating species
|
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
|
WO2010011684A2
(en)
*
|
2008-07-21 |
2010-01-28 |
The Regents Of The University Of California |
Prodrug and fluoregenic compositions and methods for using the same
|
|
CN102264728B
(zh)
|
2008-09-15 |
2015-02-04 |
加利福尼亚大学董事会 |
用于调节ire1、src和abl活性的方法和组合物
|
|
ES2624622T3
(es)
|
2008-12-30 |
2017-07-17 |
Rigel Pharmaceuticals, Inc. |
Inhibidores de pirimidindiamina cinasa
|
|
PL2565193T3
(pl)
|
2009-01-23 |
2014-07-31 |
Rigel Pharmaceuticals Inc |
Kompozycje i sposoby hamowania szlaku JAK
|
|
EP2393488B1
(de)
*
|
2009-02-06 |
2019-06-19 |
University Of Southern California |
Therapeutische zusammensetzungen mit monoterpenen
|
|
CA2749352A1
(en)
*
|
2009-02-20 |
2010-09-10 |
Micro Labs Limited |
Storage stable prostaglandin product
|
|
CN102470135A
(zh)
|
2009-07-28 |
2012-05-23 |
里格尔药品股份有限公司 |
抑制jak途径的组合物和方法
|
|
KR101906146B1
(ko)
|
2009-08-17 |
2018-10-10 |
메모리얼 슬로안-케터링 캔서 센터 |
열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
|
|
PT2473049T
(pt)
|
2009-09-04 |
2019-03-04 |
Sunesis Pharmaceuticals Inc |
Inibidores de tirosina quinase de bruton
|
|
US9029359B2
(en)
|
2009-09-04 |
2015-05-12 |
Biogen Idec Ma, Inc. |
Heteroaryl Btk inhibitors
|
|
HRP20160967T1
(hr)
|
2009-10-06 |
2016-10-07 |
Millennium Pharmaceuticals, Inc. |
Heterociklički spojevi korisni kao pdk1 inhibitori
|
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
|
DK2853262T3
(en)
|
2009-10-26 |
2017-03-06 |
Sephoris Pharmaceuticals Llc |
Treatment of sunburn using analgesics and antihistamines
|
|
CA2781056A1
(en)
|
2009-11-16 |
2011-05-19 |
Rebecca Maglathlin |
Kinase inhibitors
|
|
MX347591B
(es)
|
2009-12-10 |
2017-05-03 |
The Regents Of The Univ Of California * |
Agentes de enlace amiloides.
|
|
EP2542082B8
(de)
|
2010-03-03 |
2020-06-17 |
Neonc Technologies Inc. |
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT (S)-Perillylalkohol
|
|
JP6155187B2
(ja)
|
2010-03-30 |
2017-06-28 |
ヴァーセオン コーポレイション |
トロンビンの阻害剤としての多置換芳香族化合物
|
|
AU2011242562B2
(en)
|
2010-04-24 |
2016-10-13 |
Mycovia Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
AU2011282742B2
(en)
|
2010-07-28 |
2015-08-27 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
|
US20160038600A1
(en)
|
2012-08-03 |
2016-02-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising poh derivatives
|
|
DK3685835T3
(da)
|
2010-08-27 |
2025-07-21 |
Univ Southern California |
Farmaceutiske sammensætninger, der omfatter derivater af perillylalkohol
|
|
US9056855B2
(en)
|
2010-10-28 |
2015-06-16 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
US9273028B2
(en)
|
2010-10-29 |
2016-03-01 |
Biogen Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
|
EP3483147A1
(de)
|
2010-11-13 |
2019-05-15 |
Innocrin Pharmaceuticals, Inc. |
Metalloenzyminhibitorverbindungen
|
|
EA201390876A1
(ru)
|
2010-12-13 |
2013-12-30 |
Вайамет Фармасьютикалс, Инк. |
Соединения, ингибирующие металлоферменты
|
|
ES3056006T3
(en)
|
2010-12-17 |
2026-02-17 |
Univ Southern California |
Methods and devices for using isoperillyl alcohol
|
|
BR112013020719B1
(pt)
|
2011-02-14 |
2018-04-17 |
Allergan, Inc. |
Composições de derivados de bimatoprost tipo éster e métodos
|
|
US9169182B2
(en)
|
2011-02-25 |
2015-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chrysophaentin analogs that inhibit FtsZ protein
|
|
EP3682896A1
(de)
|
2011-04-28 |
2020-07-22 |
University of Southern California |
Aus menschlichen myeloiden suppressorzellen gewonnene krebsmarker
|
|
CA2836449C
(en)
|
2011-05-17 |
2021-04-27 |
The Regents Of The University Of California |
Kinase inhibitors
|
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
EA025496B1
(ru)
|
2011-05-17 |
2016-12-30 |
Принсипиа Биофарма Инк. |
Ингибиторы тирозинкиназы
|
|
JP2014521594A
(ja)
|
2011-05-25 |
2014-08-28 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
長持続期間デュアルホルモンコンジュゲート
|
|
IN2014MN00093A
(de)
|
2011-06-19 |
2015-06-19 |
Viamet Pharmaceuticals Inc |
|
|
WO2012177635A1
(en)
|
2011-06-19 |
2012-12-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
EA025266B1
(ru)
|
2011-06-23 |
2016-12-30 |
Ваймет Фармасьютикалс, Инк. |
Соединения, ингибирующие металлоферменты
|
|
CA2843854A1
(en)
|
2011-07-01 |
2013-01-10 |
The Regents Of The University Of California |
Herpes virus vaccine and methods of use
|
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
|
EP2771341A4
(de)
|
2011-10-28 |
2015-09-23 |
Univ Texas |
Neue zusammensetzungen und verfahren zur behandlung von krebs
|
|
EP3351541A1
(de)
|
2011-12-11 |
2018-07-25 |
Viamet Pharmaceuticals (NC), Inc. |
Metalloenzyminhibitorverbindungen
|
|
ES2774267T3
(es)
|
2012-01-20 |
2020-07-20 |
Mycovia Pharmaceuticals Inc |
Compuestos inhibidores de metaloenzimas
|
|
CA2865504A1
(en)
|
2012-03-23 |
2013-09-26 |
Oxigene, Inc. |
Compositions and methods for inhibition of cathepsins
|
|
EP2836482B1
(de)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur behandlung von krebs
|
|
US20130310340A1
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
|
US9353087B2
(en)
|
2012-06-08 |
2016-05-31 |
Biogen Ma Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
WO2013188452A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
|
TR201900863T4
(tr)
|
2012-08-27 |
2019-02-21 |
Allergan Inc |
Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
|
|
ME03455B
(de)
|
2012-09-10 |
2020-01-20 |
Principia Biopharma Inc |
Pyrazolopyrimidinverbindungen als kinaseinhibitoren
|
|
MX2015003874A
(es)
|
2012-09-26 |
2015-12-16 |
Univ California |
Modulacion de ire1.
|
|
JP6465803B2
(ja)
|
2012-10-22 |
2019-02-06 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
Ｅｔｐ誘導体
|
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
|
WO2014124458A1
(en)
|
2013-02-11 |
2014-08-14 |
The Regents Of The University Of California |
Compositions and methods for treating neurodegenerative diseases
|
|
EP2968296B1
(de)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gammasekretasemodulatoren
|
|
US9321745B2
(en)
|
2013-03-12 |
2016-04-26 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid IP receptors
|
|
WO2014143591A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
|
|
WO2014165307A2
(en)
|
2013-03-14 |
2014-10-09 |
The Regents Of The University Of California |
Modulation of k2p channels
|
|
CA3123075C
(en)
|
2013-03-14 |
2023-09-19 |
The Regents Of The University Of California |
Thiosaccharide mucolytic agents
|
|
CA2902914A1
(en)
|
2013-03-14 |
2014-09-25 |
City Of Hope |
5-bromo-indirubins
|
|
HK1214252A1
(zh)
|
2013-03-15 |
2016-07-22 |
Verseon Corporation |
作為凝血酶抑制劑的鹵代吡唑
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
CN110179795A
(zh)
|
2013-03-15 |
2019-08-30 |
维颂公司 |
作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
|
|
EA201892769A3
(ru)
|
2013-03-15 |
2019-08-30 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Сложные диэфиры ациклических нуклеозидфосфонатов
|
|
HK1220385A1
(zh)
|
2013-03-15 |
2017-05-05 |
Allergan, Inc. |
用於增加瘦素生成的比马前列素
|
|
CA2904794C
(en)
|
2013-03-15 |
2021-11-23 |
Peter Walter |
Modulators of the eif2alpha pathway
|
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
WO2014190207A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
|
WO2015009742A2
(en)
|
2013-07-15 |
2015-01-22 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
|
DK3035926T3
(da)
|
2013-08-19 |
2020-08-31 |
Univ California |
Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
|
|
WO2015026935A2
(en)
|
2013-08-20 |
2015-02-26 |
City Of Hope |
Hdac8 inhibitors for treating cancer
|
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
US10280169B2
(en)
|
2013-12-11 |
2019-05-07 |
Biogen Ma Inc. |
Biaryl bruton's tyrosine kinase inhibitors
|
|
EP3080103B9
(de)
|
2013-12-11 |
2018-09-19 |
Biogen MA Inc. |
Zur behandlung von erkrankungen des menschen in der onkologie, neurologie und immunologie geeignete biarylverbindungen
|
|
MX2016008418A
(es)
|
2013-12-23 |
2017-01-11 |
Memorial Sloan Kettering Cancer Center |
Metodos y reactivos para el radiomarcaje.
|
|
HUE044329T2
(hu)
*
|
2014-01-22 |
2019-10-28 |
Visufarma B V |
Iota-karragént tartalmazó készítmény vírusos kötõhártya-gyulladás ellen
|
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
|
EP3104706B1
(de)
|
2014-02-11 |
2022-03-23 |
Mitokinin, Inc. |
Zusammensetzungen und verfahren damit zur behandlung von neurodegenerativer und mitochondrialer erkrankung
|
|
WO2015123595A1
(en)
|
2014-02-14 |
2015-08-20 |
The Regents Of The University Of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
|
TR201902864T4
(tr)
|
2014-02-20 |
2019-03-21 |
Allergan Inc |
Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.
|
|
PT3107544T
(pt)
|
2014-02-21 |
2021-01-05 |
Principia Biopharma Inc |
Sais e forma sólida de um inibidor de btk
|
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
|
AU2015235929B2
(en)
|
2014-03-26 |
2019-02-14 |
City Of Hope |
Treatment of BRCA1-defective cancer or resistant cancers
|
|
ES2908240T3
(es)
|
2014-04-07 |
2022-04-28 |
Univ California |
Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
|
|
KR102461419B1
(ko)
|
2014-05-13 |
2022-11-02 |
메모리얼 슬로안 케터링 캔서 센터 |
Hsp70 조정물질 및 이의 제조 및 이용 방법
|
|
US10166246B2
(en)
|
2014-05-27 |
2019-01-01 |
City Of Hope |
TGR5 agonist complexes for treating diabetes and cancer
|
|
WO2016004383A1
(en)
|
2014-07-03 |
2016-01-07 |
City Of Hope |
Tumor-selective ctla-4 antagonists
|
|
WO2016018917A2
(en)
|
2014-07-28 |
2016-02-04 |
The Regents Of The University Of Califoria |
Compositions and methods of making polymerized nucleic acids
|
|
US10980744B2
(en)
|
2014-08-08 |
2021-04-20 |
The Regents Of The University Of California |
High density peptide polymers
|
|
WO2016040806A1
(en)
|
2014-09-11 |
2016-03-17 |
The Regents Of The University Of California |
mTORC1 INHIBITORS
|
|
BR112017005111B1
(pt)
|
2014-09-15 |
2023-02-14 |
The Regents Of The University Of California |
Compostos análogos de nucleotídeo acíclico, composição farmacêutica contendo tais compostos, e usos da composição no tratamento de uma infecção por papilomavírus
|
|
US10189810B2
(en)
|
2014-09-17 |
2019-01-29 |
Verseon Corporation |
Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
|
ES2826443T3
(es)
|
2014-09-25 |
2021-05-18 |
Araxes Pharma Llc |
Inhibidores de proteínas mutantes KRAS G12C
|
|
CA2962766A1
(en)
|
2014-10-02 |
2016-04-07 |
Allergan, Inc. |
Ester prodrugs of gamma-lactams and their use
|
|
US10485797B2
(en)
|
2014-12-18 |
2019-11-26 |
Principia Biopharma Inc. |
Treatment of pemphigus
|
|
EP3244907B1
(de)
|
2015-01-13 |
2020-02-19 |
City of Hope |
Peptid-linkermasken mit ctla4-bindenden proteinen
|
|
AU2016206475B2
(en)
|
2015-01-16 |
2021-11-04 |
City Of Hope |
Cell penetrating antibodies
|
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
|
JP6674957B2
(ja)
|
2015-02-12 |
2020-04-01 |
ネオンク テクノロジーズ インク． |
ペリリルアルコール誘導体を含む医薬組成物
|
|
CN113546174A
(zh)
|
2015-02-25 |
2021-10-26 |
加利福尼亚大学董事会 |
用于治疗病症的5ht激动剂
|
|
BR112017018198A2
(pt)
|
2015-02-27 |
2018-04-10 |
Curtana Pharmaceuticals Inc |
inibição da atividade de olig2
|
|
WO2016138533A2
(en)
|
2015-02-27 |
2016-09-01 |
The Regents Of The University Of California |
Small molecules that enable cartilage rejuvanation
|
|
CN107405333A
(zh)
|
2015-02-27 |
2017-11-28 |
维颂公司 |
作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
|
|
CN107614523A
(zh)
|
2015-03-30 |
2018-01-19 |
希望之城 |
机械互锁复合物
|
|
JP2018513853A
(ja)
|
2015-04-10 |
2018-05-31 |
アラクセス ファーマ エルエルシー |
置換キナゾリン化合物およびその使用方法
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
AU2016247858B2
(en)
|
2015-04-17 |
2020-10-15 |
Ludwig Institute For Cancer Research Ltd. |
PLK4 inhibitors
|
|
AU2016253149B2
(en)
|
2015-04-24 |
2022-05-19 |
The Regents Of The University Of California |
Modulators of ROR1-ROR2 binding
|
|
PT3294764T
(pt)
|
2015-05-15 |
2021-02-15 |
Hope City |
Composições de recetores de antigénios quiméricos
|
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
|
US10765696B2
(en)
|
2015-06-10 |
2020-09-08 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
|
EP3307732A1
(de)
|
2015-06-10 |
2018-04-18 |
Biogen MA Inc. |
Formen und zusammensetzungen von biarylinhibitoren der bruton-tyrosinkinase
|
|
TW201718572A
(zh)
|
2015-06-24 |
2017-06-01 |
普林斯匹亞生物製藥公司 |
酪胺酸激酶抑制劑
|
|
JP7073109B2
(ja)
|
2015-07-02 |
2022-05-23 |
シティ・オブ・ホープ |
ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
JP6994454B2
(ja)
|
2015-08-04 |
2022-01-14 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
ベンズアゾール化合物ならびに該化合物の作製方法および使用方法
|
|
TW201718023A
(zh)
|
2015-08-06 |
2017-06-01 |
世代好公司 |
細胞滲透性蛋白質－抗體結合物及使用方法
|
|
US11136301B2
(en)
|
2015-08-31 |
2021-10-05 |
The Regents of the University of California, A California Corporation et al. |
Broad spectrum antiviral compounds and uses thereof
|
|
WO2017040982A1
(en)
|
2015-09-02 |
2017-03-09 |
The Regents Of The University Of California |
Her3 ligands and uses thereof
|
|
CN108349900A
(zh)
|
2015-09-04 |
2018-07-31 |
希望之城 |
雄激素受体拮抗剂
|
|
EP3349754B9
(de)
|
2015-09-17 |
2025-10-22 |
City of Hope |
Pcna-inhibitoren
|
|
CA2998294C
(en)
|
2015-09-25 |
2023-09-12 |
Ludwig Institute For Cancer Research Ltd |
3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
|
|
EP3356354A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356353A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10801026B2
(en)
|
2015-10-15 |
2020-10-13 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
JP2018533939A
(ja)
|
2015-10-19 |
2018-11-22 |
アラクセス ファーマ エルエルシー |
Ｒａｓの阻害剤をスクリーニングするための方法
|
|
EP3364976B1
(de)
|
2015-10-19 |
2026-03-18 |
Board of Regents, The University of Texas System |
Piperazinyl-norbenzomorphan-verbindungen und verfahren zur verwendung davon
|
|
JP7034078B2
(ja)
|
2015-10-23 |
2022-03-11 |
イーアールエックス ファーマシューティカルズ インコーポレイテッド |
セラストロールの類似体
|
|
US20190015410A1
(en)
|
2015-10-23 |
2019-01-17 |
Sunesis Pharmaceuticals, Inc. |
Heterocyclic pdk1 inhibitors for use to treat cancer
|
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
WO2017100714A1
(en)
|
2015-12-10 |
2017-06-15 |
City Of Hope |
Cell penetrating cyanine-coupled antibodies
|
|
BR112018012934B1
(pt)
|
2015-12-24 |
2023-11-07 |
The Regents Of The University Of California |
Reguladores cftr e métodos de uso dos mesmos
|
|
AU2016379444B2
(en)
|
2015-12-24 |
2021-04-29 |
The Regents Of The University Of California |
CFTR regulators and methods of use thereof
|
|
KR102240920B1
(ko)
|
2015-12-30 |
2021-04-16 |
브이피에스-3, 엘엘씨 |
금속 효소 억제 화합물
|
|
CA3010445A1
(en)
|
2016-01-05 |
2017-07-13 |
The Regents Of The University Of California |
Benzothiazole amphiphiles
|
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
|
WO2017161344A1
(en)
|
2016-03-17 |
2017-09-21 |
The Regants Of The University Of California |
Compositions and methods for treating parasitic diseases
|
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
EP3458448B1
(de)
|
2016-04-25 |
2021-06-23 |
Forma Therapeutics, Inc. |
Fasn-hemmer zur behandlung der nicht-alkoholischen steatohepatitis
|
|
EP3448519A4
(de)
|
2016-04-29 |
2020-01-22 |
Board Of Regents, The University Of Texas System |
Sigma-rezeptor-bindemittel
|
|
TWI763668B
(zh)
|
2016-05-05 |
2022-05-11 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
UA121354C2
(uk)
|
2016-05-12 |
2020-05-12 |
Анакор Фармасутікалз, Інк. |
Нові сполуки для лікування паразитарних захворювань
|
|
US10918648B2
(en)
|
2016-05-26 |
2021-02-16 |
The Regents Of The University Of California |
Estrogen receptor modulator combinations
|
|
JP7065840B2
(ja)
|
2016-06-27 |
2022-05-12 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
２，４－ジアミノ－ピリミジン化合物ならびに該化合物の作製法および使用法
|
|
MA45547A
(fr)
|
2016-06-29 |
2019-05-08 |
Principia Biopharma Inc |
Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
|
|
US11045493B2
(en)
|
2016-07-11 |
2021-06-29 |
The Regents Of The University Of California |
Synthetic melanin nanoparticles and uses thereof
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
JP7214632B2
(ja)
|
2016-07-21 |
2023-01-30 |
バイオジェン エムエー インク． |
ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
|
|
HUE059242T2
(hu)
|
2016-07-29 |
2022-11-28 |
Rapt Therapeutics Inc |
Azetidin-származékok mint kemokin receptor modulátorok és felhasználásuk
|
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
|
AU2017327384B2
(en)
|
2016-09-13 |
2021-05-20 |
The Jackson Laboratory |
Targeted enhanced DNA demethylation
|
|
EP3512520B1
(de)
|
2016-09-15 |
2023-06-21 |
City of Hope |
Dithio-derivate von epidithiodiketopiperazine (etp)
|
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3523289A1
(de)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclische verbindungen als ras-inhibitoren und verfahren zur verwendung davon
|
|
CN110099899B
(zh)
|
2016-10-26 |
2024-01-02 |
里格尔药品股份有限公司 |
用作irak抑制剂的噁唑衍生物及其制备方法
|
|
US10414753B2
(en)
|
2016-10-26 |
2019-09-17 |
Rigel Pharmaceuticals, Inc. |
Amide compounds and method for making and using
|
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
|
EP3547836B1
(de)
|
2016-11-30 |
2024-08-21 |
University of Southern California |
Perillylalkohol-3 bromopyruvat-konjugat und verfahren zur behandlung von krebs
|
|
BR112019012263A2
(pt)
|
2016-12-15 |
2020-01-28 |
The Regents Of The University Of California |
composições e métodos para tratar câncer
|
|
FI3562487T3
(fi)
|
2016-12-29 |
2023-12-14 |
Ji Xing Pharmaceuticals Hong Kong Ltd |
Metalloentsyymi-inhibiittoriyhdisteitä
|
|
EP3562306B1
(de)
|
2016-12-29 |
2025-02-26 |
Ji Xing Pharmaceuticals Hong Kong Limited |
Metalloenzym-inhibitor-verbindungen
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
EP3573954A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fusionierte bicyclische benzoheteroaromatische verbindungen und verfahren zur verwendung davon
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
|
AU2018271990A1
(en)
|
2017-05-25 |
2019-12-12 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
EP3641545A4
(de)
|
2017-06-21 |
2021-02-24 |
Mitokinin, Inc. |
Zusammensetzungen und verfahren damit zur behandlung von neurodegenerativer und mitochondrialer erkrankung
|
|
CA3068305A1
(en)
|
2017-06-29 |
2019-01-03 |
Rigel Pharmaceuticals, Inc. |
Kinase inhibitors and methods for making and using
|
|
WO2019006371A1
(en)
|
2017-06-30 |
2019-01-03 |
City Of Hope |
COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY
|
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
|
JP2020536072A
(ja)
|
2017-09-29 |
2020-12-10 |
ジェネンテック， インコーポレイテッド |
ペプチド抗生物質複合体およびその使用方法
|
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
|
|
WO2019074962A1
(en)
|
2017-10-10 |
2019-04-18 |
Syros Pharmaceuticals, Inc. |
PYRROLOTRIAZINE COMPOUNDS AND METHODS FOR INHIBITING TAM KINASES
|
|
WO2019079819A1
(en)
|
2017-10-20 |
2019-04-25 |
City Of Hope |
COMPOSITION AND METHOD FOR ACTIVATION OF LATENT HUMAN IMMUNODEFICIENCY VIRUS (HIV)
|
|
AU2018358157B2
(en)
|
2017-11-02 |
2023-03-09 |
Abbvie Inc. |
Modulators of the integrated stress pathway
|
|
WO2019090088A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
CA3080808A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
WO2019090090A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
WO2019090074A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
JP2021501781A
(ja)
|
2017-11-02 |
2021-01-21 |
カリコ ライフ サイエンシーズ エルエルシー |
統合的ストレス経路の調節剤
|
|
RU2020118594A
(ru)
|
2017-11-06 |
2021-12-09 |
Рапт Терапьютикс, Инк. |
Противораковые агенты
|
|
EP3720560A4
(de)
|
2017-12-06 |
2022-01-05 |
Ludwig Institute for Cancer Research Ltd |
Verfahren zur behandlung von krebs mit plk4-inhibitoren
|
|
PL3720438T3
(pl)
|
2017-12-07 |
2024-03-18 |
Amplyx Pharmaceuticals, Inc. |
Heterocyklicznie podstawione pochodne pirydyny jako środki przeciwgrzybicze
|
|
US20210292410A1
(en)
|
2017-12-07 |
2021-09-23 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
|
EA202091475A1
(ru)
|
2017-12-15 |
2020-09-09 |
Пирамид Байосайенсиз, Инк. |
ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
|
|
WO2019126037A1
(en)
|
2017-12-19 |
2019-06-27 |
City Of Hope |
Modified tracrrnas grnas, and uses thereof
|
|
CA3088529A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
EP3740207A4
(de)
|
2018-01-16 |
2021-10-13 |
Syros Pharmaceuticals, Inc. |
Hemmer der cyclinabhängigen kinase 7 (cdk7)
|
|
CN111971279B
(zh)
|
2018-01-26 |
2025-09-09 |
拉普特医疗公司 |
趋化因子受体调节剂及其用途
|
|
CN111936125B
(zh)
|
2018-02-08 |
2025-03-04 |
南加州大学 |
穿透血脑屏障的方法
|
|
KR20200143376A
(ko)
|
2018-03-13 |
2020-12-23 |
샤이어 휴먼 지네틱 테라피즈 인크. |
혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
|
|
EP4438124A3
(de)
|
2018-04-27 |
2024-12-18 |
Spruce Biosciences, Inc. |
Verfahren zur behandlung von hoden- und eierstock-nebennierentumoren
|
|
IL300091A
(en)
|
2018-05-01 |
2023-03-01 |
Revolution Medicines Inc |
C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
|
|
CN112368289B
(zh)
|
2018-05-01 |
2024-02-20 |
锐新医药公司 |
作为mtor抑制剂的c26-连接的雷帕霉素类似物
|
|
EA202092580A1
(ru)
|
2018-05-03 |
2021-04-07 |
Ригел Фармасьютикалз, Инк. |
Соединения, ингибирующие rip1, а также способы их получения и применения
|
|
UA128160C2
(uk)
|
2018-05-03 |
2024-04-24 |
Райджел Фармасутікалс, Інк. |
Сполуки, що інгібують rip1, а також способи їх одержання та застосування
|
|
US11931345B2
(en)
|
2018-05-04 |
2024-03-19 |
Cirius Therapeutics, Inc. |
Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases
|
|
WO2019236631A1
(en)
|
2018-06-05 |
2019-12-12 |
Rapt Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
|
WO2019236901A1
(en)
|
2018-06-06 |
2019-12-12 |
The Regents Of The University Of California |
Estrogen receptor inhibitors and uses therof
|
|
KR20250133466A
(ko)
|
2018-06-21 |
2025-09-05 |
칼리코 라이프 사이언시스 엘엘씨 |
단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법
|
|
CN112638371A
(zh)
|
2018-06-25 |
2021-04-09 |
安普利克斯制药公司 |
被杂环和氨基取代的吡啶衍生物
|
|
MX2021000887A
(es)
|
2018-08-01 |
2021-03-31 |
Araxes Pharma Llc |
Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
|
|
CN112867503A
(zh)
|
2018-08-24 |
2021-05-28 |
希望之城 |
掩蔽的细胞因子缀合物
|
|
CA3110860A1
(en)
|
2018-08-31 |
2020-03-05 |
Amplyx Pharmaceuticals, Inc. |
Compounds and methods for treating fungal infections
|
|
EP3849620A4
(de)
|
2018-09-10 |
2022-08-17 |
The Regents of the University of California |
Dithiolsaccharid-mucolytika und verwendungen davon
|
|
TW202545902A
(zh)
|
2018-10-11 |
2025-12-01 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
|
US20220000880A1
(en)
|
2018-11-01 |
2022-01-06 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
|
EP3856742B1
(de)
|
2018-11-01 |
2024-10-02 |
Lynk Pharmaceuticals Co. Ltd. |
Tricyclische janus-kinase-1-inhibitoren und zusammensetzungen und verfahren dafür
|
|
WO2020118683A1
(en)
|
2018-12-14 |
2020-06-18 |
Lynk Pharmaceuticals Co. Ltd. |
Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
|
|
CA3126224A1
(en)
|
2019-01-08 |
2020-07-16 |
Corxel Pharmaceuticals Hong Kong Limited |
Metalloenzyme inhibitor compounds
|
|
PE20252767A1
(es)
|
2019-03-14 |
2025-12-22 |
Calico Life Sciences Llc |
Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos
|
|
PE20220572A1
(es)
|
2019-04-30 |
2022-04-20 |
Calico Life Sciences Llc |
Moduladores de la via integrada del estres
|
|
CN121489917A
(zh)
|
2019-05-15 |
2026-02-10 |
贝克森生物医药公司 |
用于皮下注射的氯胺酮制剂
|
|
US20200377518A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
|
EP3983533B1
(de)
|
2019-06-14 |
2025-01-08 |
Children's Hospital Medical Center |
Ube2n-inhibitoren zur verwendung bei der behandlung von akuter myelomonozytischer leukämie (aml-m4) und/oder akuter monocytischer leukämie (aml-m5).
|
|
BR112022001418A2
(pt)
|
2019-08-08 |
2022-06-07 |
Rigel Pharmaceuticals Inc |
Compostos e método para tratar a síndrome de liberação de citocinas
|
|
ES2970382T3
(es)
|
2019-08-14 |
2024-05-28 |
Rigel Pharmaceuticals Inc |
Método para bloquear o mejorar el síndrome de liberación de citocinas
|
|
CN121159524A
(zh)
|
2019-08-30 |
2025-12-19 |
里格尔药品股份有限公司 |
吡唑化合物，其配制品以及使用所述化合物和/或配制品的方法
|
|
CA3149926A1
(en)
|
2019-09-06 |
2021-03-11 |
Yan Chen |
Rip1 inhibitory compounds and methods for making and using the same
|
|
KR102793185B1
(ko)
|
2019-09-06 |
2025-04-09 |
리겔 파마슈티칼스, 인크. |
Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
|
|
MX2022003192A
(es)
|
2019-09-18 |
2022-04-11 |
Novartis Ag |
Proteinas de fusion nkg2d y sus usos.
|
|
EP4031547B1
(de)
|
2019-09-18 |
2024-07-17 |
Takeda Pharmaceutical Company Limited |
Plasma-kallikreininhibitoren und verwendungen dafür
|
|
CN114667289B
(zh)
|
2019-09-18 |
2025-08-26 |
武田药品工业有限公司 |
杂芳基血浆激肽释放酶抑制剂
|
|
US12516145B2
(en)
|
2019-09-30 |
2026-01-06 |
Northwestern University |
Bioactive peptide brush polymers via photoinduced reversible-deactivation radical polymerization
|
|
TWI877239B
(zh)
|
2019-10-14 |
2025-03-21 |
美商普林斯匹亞生物製藥公司 |
藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
|
|
WO2021087076A1
(en)
|
2019-10-30 |
2021-05-06 |
Northwestern University |
Selenium-containing analogues of pheomelanin and related materials and methods of making
|
|
AU2020378407B2
(en)
|
2019-11-07 |
2024-02-01 |
Rigel Pharmaceuticals, Inc. |
Heterocyclic RIP1 inhibitory compounds
|
|
BR112022009331A2
(pt)
|
2019-11-13 |
2022-08-09 |
Rapt Therapeutics Inc |
Formas cristalinas do receptor de quimiocina c c antagonista tipo 4 e usos das mesmas
|
|
WO2021127499A1
(en)
|
2019-12-18 |
2021-06-24 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
|
JP2023511105A
(ja)
|
2020-01-22 |
2023-03-16 |
プリンシピア バイオファーマ インコーポレイテッド |
２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態
|
|
JP7767301B2
(ja)
|
2020-04-15 |
2025-11-11 |
ピラミッド バイオサイエンシズ インコーポレイテッド |
チロシン受容体キナーゼ阻害剤を調製する方法
|
|
KR20240096817A
(ko)
|
2020-05-19 |
2024-06-26 |
사이빈 아이알엘 리미티드 |
중수소화된 트립타민 유도체 및 사용 방법
|
|
GB202008919D0
(en)
*
|
2020-06-11 |
2020-07-29 |
Univ Birmingham |
Polysaccharide conpositions and therapeutic gels
|
|
US12122741B2
(en)
|
2020-08-18 |
2024-10-22 |
Cybin Irl Limited |
Therapeutic phenethylamine compositions and methods of use
|
|
CA3194653A1
(en)
|
2020-10-02 |
2022-04-07 |
Mitokinin, Inc. |
Compositions and methods of treating kidney disease and fibrosis
|
|
MX2023005056A
(es)
|
2020-11-02 |
2023-07-24 |
Trethera Corp |
Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos.
|
|
JP2023551145A
(ja)
|
2020-11-18 |
2023-12-07 |
ベクソン バイオメディカル，インク． |
医薬化合物の錯化剤塩製剤
|
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
|
WO2022187303A1
(en)
|
2021-03-03 |
2022-09-09 |
Rigel Pharmaceuticals, Inc. |
A method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
AR125587A1
(es)
|
2021-03-11 |
2023-08-02 |
Rigel Pharmaceuticals Inc |
Inhibidores heterocíclicos de la quinasa de rip1
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
CN117396473A
(zh)
|
2021-03-17 |
2024-01-12 |
武田药品工业株式会社 |
血浆激肽释放酶的咪唑并吡啶基抑制剂
|
|
US20240226106A1
(en)
|
2021-03-17 |
2024-07-11 |
Shire Human Genetic Therapies, Inc. |
Inhibitors of plasma kallikrein
|
|
BR112023018619A2
(pt)
|
2021-03-17 |
2023-11-28 |
Takeda Pharmaceuticals Co |
Inibidores de heteroaril de calicreína plasmática
|
|
EP4308564A1
(de)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Polycyclische inhibitoren von plasmakallikrein
|
|
US20240382482A1
(en)
|
2021-03-17 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors
|
|
AU2022258467A1
(en)
|
2021-04-13 |
2023-11-30 |
Contineum Therapeutics, Inc. |
Crystalline compound of muscarinic acetylcholine m1 receptor antagonists
|
|
KR20240153566A
(ko)
|
2022-02-15 |
2024-10-23 |
사이빈 아이알엘 리미티드 |
치료적 펜에틸아민 조성물, 및 사용 방법
|
|
CA3244130A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
PHENETYLAMINE DERIVATIVES, COMPOSITIONS AND METHODS OF USE
|
|
JP2025513716A
(ja)
|
2022-03-23 |
2025-04-30 |
ライジェル・ファーマシューティカルズ・インコーポレイテッド |
Ｉｒａｋ阻害剤としてのピリミド－２－イル－ピラゾール化合物
|
|
WO2023192479A1
(en)
|
2022-03-31 |
2023-10-05 |
Rigel Pharmaceuticals, Inc. |
Tricyclic irak inhibitors
|
|
JP2025512963A
(ja)
|
2022-04-06 |
2025-04-22 |
ラプト・セラピューティクス・インコーポレイテッド |
ケモカイン受容体モジュレータ及びその使用
|
|
CN114504550B
(zh)
*
|
2022-04-18 |
2022-08-19 |
中山大学中山眼科中心 |
一种包含甲硝唑的眼用凝胶及其制备方法
|
|
AU2023275778A1
(en)
|
2022-05-25 |
2024-12-12 |
Revolution Medicines, Inc. |
Methods of treating cancer with an mtor inhibitor
|
|
US12377036B2
(en)
|
2022-06-21 |
2025-08-05 |
Northwestern University |
Melanin hair dye with thickeners
|
|
US20250034115A1
(en)
|
2023-07-12 |
2025-01-30 |
Rapt Therapeutics, Inc. |
Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
|
|
AU2024296743A1
(en)
|
2023-07-13 |
2026-02-26 |
Comanche Biopharma Corp. |
Formulations of nucleic acid compounds and uses thereof
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
CN121889164A
(zh)
|
2023-09-26 |
2026-04-17 |
阿斯利康(瑞典)有限公司 |
包含抗steap2嵌合抗原受体t细胞的治疗组合
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|
|
EP4623919A1
(de)
|
2024-03-28 |
2025-10-01 |
Marinomed Biotech AG |
Iota-carrageenan enthaltende zusammensetzung zur behandlung von trockenem auge, nichtviraler konjunktivitis und allergischen augenerkrankungen
|
|
WO2026022243A1
(en)
|
2024-07-23 |
2026-01-29 |
The Trustees Of The University Of Pennsylvania |
Combination of a gsk-3 inhibitor and a lsd-1 inhibitor for use in the treatment of cancer
|